固本化积汤联合化疗治疗晚期非小细胞肺癌的临床观察

《固本化积汤联合化疗治疗晚期非小细胞肺癌的临床观察》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、固本化积汤联合化疗治疗晚期非小细胞肺癌的临床观察作者：王宏乐龙志芳朱士奎王贵辰高社光郑金海赵铁英康日新陈金鹏【摘要】　　目的观察固本化积汤联合化疗治疗晚期非小细胞肺癌的近期疗效。方法将194例晚期非小细胞肺癌患者随机分为2组。治疗组102例采用固本化积汤(每日1剂，1个月为1个疗程，共治疗3个疗程)配合化疗(NP或VP方案，3周为1个疗程，共治疗3个疗程)治疗。对照组92例单纯予化疗，方法同治疗组。观察2组瘤体大小变化、生活质量、体质量、主要症状改善情况及不良反应情况。结果治疗组瘤体变化有效率28.4%，对照组13.0%，2组比较差异有统计学意义(P＜0.

2、01)；治疗组治疗后卡氏评分与本组治疗前及对照组治疗后比较差异均有统计学意义(P＜0.01)；对照组治疗后体质量与本组治疗前及治疗组治疗后比较差异均有统计学意义(P＜0.01)；治疗组预后情况、症状改善情况均优于对照组(P＜0.05，P＜0.01)。治疗组不良反应情况少于对照组(P＜0.05，P＜0.01)。结论固本化积汤联合化疗治疗晚期非小细胞肺癌近期疗效优于单纯化疗，可作为晚期非小细胞肺癌的有效治疗方案。【关键词】癌非小细胞肺抗肿瘤联合化疗方案中药疗法12　　【Abstract】ObjectiveToobservetheshorttermtherape

3、uticefficacyofintegratedGubenhuajiDecoctionandchemotherapy(IGDC)intreatingnon-smallcelllungcancer(NSCLC)inⅢandⅣphase.Methods194patientswithnon-smallcellcancer(NSCLC)inⅢandⅣphasewererandomlydividedintotheIGDCgroup(n=102)andtheWesternmedicine(WM)group(n=92).PatientsintheIGDCgroupwer

4、etreatedbyintegratedGubenhuajidecoctionandchemotherapy.PatientsinWMgroupweretreatedbychemotherapy.Theexcludedordroppingoffcaseswere10inIGDCand15inWM.Clinicaltrialswereconductedin3hospitalsand3monthsoftreatmentwastakenasonetherapeuticcourse.Themainobservationindexesweretumorsize,qu

5、alityoflife,Karnofskyscores,bodyweight,adversereaction,etc.ResultsThetotaleffectiverateoftumorremissionintheIGDCgroupandWMgroupwere28.4％and13.0％,respectively.Therewasstatisticalsignificancebetweentwogroups(P<0.01).KarnofksyscoresignificantlyraisedintheIGDCgroupaftertreatmentinc

6、omparisonwiththatbeforetreatment(P<0.01).ThekarnofskyscoreinIGDCgroupwashigherthanthatinWMaftertreatment(P<0.01).Thepatient’sbodyweightsinthe2groupswereallreduced.ThereductionintheIGDCgroupwaslowerthanthatinWMgroup(P<0.01).12TheeffectintheIGDCgroupwasbetterthanthatinWMgro

7、upinaspectsofimprovingsuchtumorrelatedsymptomsascough,shortbreath,anorexia,fatigue,etc(P<0.01,P<0.05).AdversereactionintheIGDCgroupwaslesserthanthatintheWMgroup(P<0.05,P<0.01).ConclusionIGDCtherapyshowedbettershort-termefficacyintreatingpatientswithNSCLCthanWMalone.Itc

8、anbeadoptedasaneffectivetherapeut